Abstract: This invention relates to a process for preparing compounds of the Formula I,
wherein R1, R2 and Pt are as defined in the specification, which are intermediates in the synthesis of certain growth hormone secretagogue compounds. This invention further relates to processes for preparing the growth hormone secretagogues. The invention also relates to the compound of Formula I wherein R1 is H, R2 is 2,2,2-trifluoromethyl and Pt is Boc.
Abstract: A compound of the formula
wherein X, Y, Z, R2 and R3 are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated.
Abstract: This invention relates to a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein A and R1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2 is NH2; R3 and R4 are each hydrogen, halo, (C1-C4)alkyl optionally substituted with halo and the like; and X1 to X4 are each hydrogen, halo, hydroxy, (C1-C4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes and treatment of CCV infections.
Type:
Grant
Filed:
October 5, 2001
Date of Patent:
August 5, 2003
Assignee:
Pfizer Inc.
Inventors:
Timothy J. Miller, Sharon Klepfer, Albert Paul Reed, Elaine V. Jones
Abstract: A method is described in accordance with which one may select a nonsedating histamine H1-antagonist; comprising the step of determining whether a candidate H1-antagonist is a substrate for P-gp, especially P-gp expressed by MDR1 or mdr1a/1b, comprising the step of determining the brain-to-plasma AUC ratio in mdr1a/1b KO mice, and in WT mice, and selecting said candidate where the brain-to-plasma AUC ratio for said KO mice to the brain-to-plasma concentration ratio for said WT mice is 1.5 or greater.
Type:
Application
Filed:
May 30, 2002
Publication date:
July 31, 2003
Applicant:
Pfizer Inc.
Inventors:
Cuiping Chen, Jae S. Lee, John W. Watson
Abstract: The invention relates to compositions and methods for treating or preventing inflammation, including rheumatoid arthritis (RA). The method comprises administering to mammals in need thereof an effective amount of a composition containing an agent that inhibits IL-1/18 combination with a TNF inhibitor.
Type:
Application
Filed:
November 27, 2002
Publication date:
July 31, 2003
Applicant:
Pfizer Inc.
Inventors:
Christopher A. Gabel, Mark A. Dombroski
Abstract: The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a p25 (activator of the protein kinase cdk 5) polypeptide.
Abstract: The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1IMAGI promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.
Type:
Grant
Filed:
March 25, 1999
Date of Patent:
July 29, 2003
Assignees:
Pfizer, Inc., Pfizer Products, Inc.
Inventors:
B. Rajendra Krishnan, Rebecca Madura, Christine Yoder, Becky Durtschi, David A. Brake
Abstract: This invention relates to methods for preparing certain cholesteryl ester transfer protein (CETP) inhibitors and intermediates useful in the preparation of said CETP inhibitors.
Type:
Grant
Filed:
April 30, 2002
Date of Patent:
July 29, 2003
Assignee:
Pfizer Inc.
Inventors:
David B. Damon, Robert W. Dugger, Robert W. Scott
Abstract: A compound of the formula
wherein R1, R2 R3, R4 R5, R6, R7, R8, R9 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.
Type:
Grant
Filed:
November 8, 2000
Date of Patent:
July 29, 2003
Assignee:
Pfizer Inc
Inventors:
Kim F. McClure, Mark C. Noe, Michael A. Letavic, Louis S. Chupak
Abstract: The invention relates to compounds of the formula:
and to pharmaceutically acceptable salts and solvates thereof wherein Y, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings defined in the specification. The invention also relates to pharmaceutical compositions comprising said compounds and to the use of said compounds for inhibiting abnormal cell growth in mammals. The compounds of the above formula have activity as farnesyl protein transferase inhibitors.
Abstract: The present invention relates to compounds of formula I:
and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
Abstract: This application relates to processes for making compounds of formula I, and processes for making intermediates useful in the processes for making compounds of formula I.
Type:
Grant
Filed:
December 11, 2000
Date of Patent:
July 22, 2003
Assignee:
Pfizer Inc.
Inventors:
Philip Albert Carpino, Paul Andrew Dasilva-Jardine, Bruce Allen Lefker, Jerry Anthony Murry
Abstract: The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.
Type:
Grant
Filed:
April 16, 2002
Date of Patent:
July 22, 2003
Assignee:
Pfizer Inc
Inventors:
David Clive Blakemore, Justin Stephen Bryans, Sophie Caroline Williams
Abstract: Pharmaceutical compositions are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.
Type:
Application
Filed:
January 21, 2003
Publication date:
July 17, 2003
Applicant:
Pfizer Inc.
Inventors:
Jotham W. Coe, Steven B. Sands, Edmund P. Harrigan, Brian T. O'Neill, Eric J. Watsky
Abstract: This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.